S
Silvio E. Inzucchi
Researcher at Yale University
Publications - 511
Citations - 64889
Silvio E. Inzucchi is an academic researcher from Yale University. The author has contributed to research in topics: Diabetes mellitus & Type 2 diabetes. The author has an hindex of 92, co-authored 424 publications receiving 54101 citations. Previous affiliations of Silvio E. Inzucchi include University of Toronto & American Diabetes Association.
Papers
More filters
Journal ArticleDOI
Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction
Kieran F. Docherty,Modele O. Ogunniyi,Inder S. Anand,Akshay S. Desai,Mirta Diez,Jonathan G. Howlett,Jose C. Nicolau,Eileen O'Meara,Subodh Verma,Silvio E. Inzucchi,Lars Køber,Mikhail Kosiborod,Daniel Lindholm,Felipe Martinez,Olof Bengtsson,Piotr Ponikowski,Marc S. Sabatine,Mikaela Sjöstrand,Scott D. Solomon,Anna Maria Langkilde,Pardeep S. Jhund,John J.V. McMurray +21 more
TL;DR: In this article, the efficacy and safety of dapagliflozin in Black and White patients with heart failure (HF) with reduced ejection fraction (HFrEF) enrolled in DAPA-HF trial were investigated.
Journal ArticleDOI
Empagliflozin is associated with a lower risk of post-acute heart failure re-hospitalization and mortality: insights from the empa-reg outcome trial
Javed Butler,Gianluigi Savarese,Naveed Sattar,James L. Januzzi,Subodh Verma,Lars H. Lund,David Fitchett,Cordula Zeller,Jyothis T. George,Martina Brueckmann,Martina Brueckmann,Anne Pernille Ofstad,Silvio E. Inzucchi,Christoph Wanner,Bernard Zinman +14 more
TL;DR: The aim of this analysis was to investigate why hospital readmissions in patients admitted for heart failure are high and why performance measures tied to reimbursement now focus on reducing early readmissions.
Journal ArticleDOI
Glycemic management of diabetes in the perioperative setting.
TL;DR: In the following pages, I review current approaches to glycemic control in patients with diabetes undergoing surgical procedures.
Journal ArticleDOI
Diabetes mellitus as the presenting feature of extrahepatic cholangiocarcinoma in situ: case report and review of literature.
TL;DR: This unusual case of secondary diabetes emphasizes the importance of considering the precise "cause" of the hyperglycemia when the presentation is atypical, as it was in this older, lean patient without risk factors for diabetes.
Journal ArticleDOI
Dapagliflozin improves outcomes irrespective of nt-probnp concentration in patients with hfref: an analysis of the dapa-hf trial
Lars Køber,Kieran F. Docherty,Silvio E. Inzucchi,Pardeep S. Jhund,Mikhail Kosiborod,Anna Maria Langkilde,Felipe Martinez,Olof Bengtsson,Piotr Ponikowski,Marc S. Sabatine,Mikaela Sjoestrand,Scott D. Solomon,John J.V. McMurray +12 more
TL;DR: The efficacy of dapagliflozin (10mg qd), compared with placebo, according to baseline NT-proBNP level in the DAPA-HF trial is evaluated.